Scientists have announced, in their own words, a “major breakthrough” in the fight against antibiotic resistance, after a new component of antibiotics demonstrated effectiveness in the second phase of clinical trials.
Resistance to antibiotic therapy is manifested in the insensitivity of the infection to certain antibacterial agents as a result of changes in microorganisms. Antibiotic-resistant infection is a global threat. Earlier this year, it was reported about the statement of the UK’s chief medical officer, Sally Davies, that in the next 20 years people can die from the simplest operation, because there will be no effective antibiotics even against a common infection. But a small British pharmaceutical company has announced a new series of possible fast-acting drugs that could boost the effectiveness of other antibiotics.
Researchers have been studying ways to circumvent antibiotic resistance for the past 12 years. The new drugs were tested on non-dividing bacteria, which has never been done before. The scientists focused on one specific component called HT61. In the second phase of clinical trials, the drug successfully showed itself in improving the effect of old antibiotics. HT61 acted by eliminating the bacterial membrane and increasing the anti-staphylococcal effect in old antibiotics. The scientists themselves believe that the discovery will help “rejuvenate” the entire existing range of antibiotics.
In 2020, World Antimicrobial Health Week is taking place during the COVID-19 pandemic, so it is very important to focus on not allowing this epidemiological situation to exacerbate the trend of antibiotic (new component of antibiotics) resistance.
Conclusion: if there is no urgent need to use amoxil, or you decide to take it without the instructions of your doctor, then it is better not to do it. The good news is that with a new component of antibiotics, you will most likely be able to defeat antibiotic resistance.